Chagas Cardiomyopathy: Clinical Presentation and Management in the Americas

dc.creatorCatherine Pastorius Benziger
dc.creatorGabriel Assis Lopes do Carmo
dc.creatorAntonio Luiz Pinho Ribeiro
dc.date.accessioned2023-08-14T22:04:14Z
dc.date.accessioned2025-09-09T00:34:28Z
dc.date.available2023-08-14T22:04:14Z
dc.date.issued2017
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1016/j.ccl.2016.08.013
dc.identifier.issn0733-8651
dc.identifier.urihttps://hdl.handle.net/1843/57820
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofCardiology Clinics
dc.rightsAcesso Restrito
dc.subjectCardiomiopatias
dc.subjectDoença de Chagas
dc.subject.otherCardiomyopathies
dc.subject.otherChagas Disease
dc.titleChagas Cardiomyopathy: Clinical Presentation and Management in the Americas
dc.typeArtigo de periódico
local.citation.epage47
local.citation.issue1
local.citation.spage31
local.citation.volume35
local.description.resumoThe diagnosis and treatment of Chagas disease require specific knowledge about the acute and chronic forms of the disease. The initial Chagas infection is typically asymptomatic but after a decade or longer, approximately 30% of people will progress to a chronic cardiac form of Chagas cardiomyopathy with symptoms including heart failure, arrhythmias, and thromboembolism.Death is often premature and sudden due to arrhythmias or progressive heart failure.Prevention of infection through vector control programs, along with strengthened surveillance sys tems and rapid information sharing, are key to addressing the continued challenges of Chagas disease control globally
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICA
local.publisher.initialsUFMG
local.url.externahttps://www.sciencedirect.com/science/article/abs/pii/S0733865116300741?via%3Dihub

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição: